Home » KellBenx secures $2.5 million for NIPD research
KellBenx secures $2.5 million for NIPD research
April 25, 2011
KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, has secured an initial funding round of $2.5 million from four investors.
The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.